At the Pharmacology department office
Appointment on Visitation important
Topic: Drug Development And Clinical Trials
Description: Areas of research interest also include drug development. Many herbal extracts with therapeutic claims are administered for across this region without the appropriate evidence-based research studies being conducted on them. Therefore, the use of traditional medicine in disease treatment can be dissected, commencing from toxicology studies in animal models to pre-experimental models of the disease, concluding with various phases of clinical trials.
|Ph.D (Medical Biosciences)
|University of Bradford
Genetic characterisation of the prevalence of drug metaboliser CYP2D6*2 and CYP2D6*3 in tamoxifen-treated breast cancer patients
Investigation of the prevalence ofCYP2D6*3 variant 3 associated with poor metabolisers on a small cohort of breast cancer patient treated with tamoxifen. This study will test for the genetic polymorphism in the CYP2D6 enzymes, which might be beneficial when prescribing tamoxifen and potentially avoid certain adverse drug reactions, drug accumulation and toxicity associated with tamoxifen administration to poor metabolisers.DNA will be extracted from blood of breast cancer patients being treated with Tamoxifen. Polymerase chain reaction PCR will be carried out to amplify the CYP2D6 gene responsible for tamoxifen metabolism and restriction enzyme namely Hhal, which targets CYP2D6*2 associated with normal metabolism of drugs; and Mspl, which targets CYP2D6*3 associated with poor metabolism of drugs will be used in a methodology know as PCR-restriction fragment length polymorphism RFLP to assess the presence of genetic polymorphism in the CYP2D6 gene coding for the CYP2D6 enzyme.Establishing this relationship allows for the assessment of the efficacy of drugs such as tamoxifen in the treatment of breast cancer.
MAKANJUOLA SAMIRA is a Senior Lecturer at the Department of Pharmacology
MAKANJUOLA has a Ph.D in Medical Biosciences from University of Bradford